These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 8415869)

  • 41. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
    Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
    Yap EY; Battistini B; McKay KO
    Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of endothelin-converting enzyme inhibitors on big endothelin-1 induced contraction in isolated rat basilar artery.
    Zimmermann M; Jung CS; Vatter H; Raabe A; Seifert V
    Acta Neurochir (Wien); 2002 Nov; 144(11):1213-9. PubMed ID: 12434178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo.
    Fecteau MH; Honoré JC; Plante M; Labonté J; Rae GA; D'Orléans-Juste P
    Hypertension; 2005 Jul; 46(1):87-92. PubMed ID: 15956117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
    Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
    Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon.
    Hanessian S; Rogel O
    Bioorg Med Chem Lett; 1999 Aug; 9(16):2441-6. PubMed ID: 10476884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of a novel ETA receptor antagonist and phosphoramidon in renal ischemia.
    Bird JE; Webb ML; Wasserman AJ; Liu EC; Giancarli MR; Durham SK
    Pharmacology; 1995 Jan; 50(1):9-23. PubMed ID: 7899482
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutral endopeptidase inhibition: the potential of a new therapeutic approach in cardiovascular disease evolves.
    Veelken R; Schmieder RE
    J Hypertens; 2002 Apr; 20(4):599-603. PubMed ID: 11910290
    [No Abstract]   [Full Text] [Related]  

  • 49. Phosphoramidon potentiates the contractile response to endothelin-3, but not endothelin-1 in isolated airway tissue.
    McKay KO; Black JL; Armour CL
    Br J Pharmacol; 1992 Apr; 105(4):929-32. PubMed ID: 1504719
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Degradation of endothelin-1 by extracts of rat lung, kidney, and liver.
    Sirviö ML; Saijonmaa O; Metsärinne K; Fyhrquist F
    Regul Pept; 1995 Feb; 55(3):219-25. PubMed ID: 7761621
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute effect of endothelin-1 on lung oedema induced by alpha-naphthylthiourea (ANTU).
    Sipahi E; Hodoglugil U; Ercan ZS; Türker RK
    Pharmacol Res; 1996 Jun; 33(6):375-8. PubMed ID: 8971961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Daglutril for treatment of renal damage in hypertensive patients with type 2 diabetes: disappointment or hope?
    Laurent S
    Lancet Diabetes Endocrinol; 2013 Sep; 1(1):2-3. PubMed ID: 24622251
    [No Abstract]   [Full Text] [Related]  

  • 53. Role of neutral endopeptidase in the metabolism of endothelin.
    Abassi ZA; Tate JE; Golomb E; Keiser HR
    Hypertension; 1992 Jul; 20(1):89-95. PubMed ID: 1618556
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of the pharmacological effects of endothelin.
    Wilson C; Hargreaves RB
    Prog Med Chem; 1994; 31():371-410. PubMed ID: 8029479
    [No Abstract]   [Full Text] [Related]  

  • 55. Renal function as affected by inhibitors of kininase II and of neutral endopeptidase 24.11 in rats with and without desoxycorticosterone pretreatment.
    Nakagawa M; Nasjletti A
    Adv Exp Med Biol; 1989; 247B():495-9. PubMed ID: 2692417
    [No Abstract]   [Full Text] [Related]  

  • 56. Intracisternal neutral endopeptidase-24.11 inhibitors produce inhibition in gastric acid output: independence from opiate, bombesin, or neurotensin-mediated mechanisms.
    Stephens RL; LePard KJ; Mohammed JR; Ward PE
    Regul Pept; 1993 Jul; 46(3):549-55. PubMed ID: 8210514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endothelin 1 hydrolysis by rat kidney membranes.
    Yamaguchi T; Fukase M; Arao M; Sugimoto T; Chihara K
    FEBS Lett; 1992 Sep; 309(3):303-6. PubMed ID: 1516701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement of postischemic hepatic microhemodynamics by an endothelin converting enzyme inhibitor (FR 901533).
    Uhlmann D; Witzigmann H; Senninger N; Hauss J; Spiegel H
    Transplant Proc; 2001 Jun; 33(4):2549-50. PubMed ID: 11406245
    [No Abstract]   [Full Text] [Related]  

  • 59. Endothelin converting enzyme protects postischemic liver.
    Witzigmann H; Uhlmann D; Senninger N; Hauss J; Spiegel H
    Transplant Proc; 2001; 33(1-2):866. PubMed ID: 11267107
    [No Abstract]   [Full Text] [Related]  

  • 60. In vitro degradation of endothelin-1 by endopeptidase 24.11 (enkephalinase).
    Fagny C; Michel A; Léonard I; Berkenboom G; Fontaine J; Deschodt-Lanckman M
    Peptides; 1991; 12(4):773-8. PubMed ID: 1788141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.